Drug Combo Effective For Advanced Breast Cancer

A pair of studies at UCLA’s Jonsson Cancer Center that takes laboratory science to the patients’ bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer. The results of the studies, the first done on cell lines in the laboratory and the second translated into more than 120 patients in two Phase II clinical trials, appear May 18 in the peer reviewed Journal of the National Cancer Institute.

Back to news